TIMP1, a key tissue inhibitor of metalloproteinase that regulates most matrix metalloproteinases, was usually found to be increased in renal cell carcinoma (RCC) and could affect the efficiency of radiotherapy (Smyth et al., 2007). This evidence concerns the gene TIMP1 and hereditary clear cell renal cell carcinoma.